We collaborate
to accelerate
Partnering with clinical
experts and KOLs
We work closely with clinical experts and key opinion leaders from leading hospitals and academic institutions to translate innovative ideas into differentiated therapeutic programs. Galenicap provides end-to-end support, from early concept development and formulation strategy to GMP manufacturing and clinical execution. If you have a concept to improve or reposition an existing medicine, we offer the expertise and resources to bring it forward and create meaningful impact for patients.
Advancing assets with Generic and Pharma Partners
We partner with generic drug companies and pharma to develop enhanced versions of established medicines and advance them to clinical proof of concept. Our programs are designed for efficient progression through early clinical stages, creating well-positioned assets for further development, registration, and commercialization. We welcome discussions with partners interested in accessing or co-developing differentiated clinical programs.
Co-investing through structured SPV opportunities
Galenicap is accustomed to financing comprehensive development programs, covering the entire spectrum from ideation to proof-of-concept. While we often independently fund each project (in the form of a Special Purpose Vehicle or SPV), we also welcome co-investments from external partners. This includes collaboration with third-party investors like university funds, niche investment firms, family offices with a specific disease focus, and pharmaceutical or generic drug companies. If you're keen on exploring investment opportunities with Galenicap or any of our projects, we encourage you to reach out. Let's discuss potential synergies and possibilities.
